Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

NCT07198724 is registered in ClinicalTrials.gov with Kristina A. Fanucci as lead sponsor.

NCT NCT07198724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07198724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Lead sponsor
Kristina A. Fanucci
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 17, 2025
Completion date
June 1, 2038
Enrollment
65 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer female, her2 low breast carcinoma, her2-negative breast cancer, metastatic breast cancer